Xu and co-workers designed and synthesized a series of coumarin-based MEK1/2 PROTAC MEK1/2 degraders based on a coumarin derivative which was a potent non-diarylamine allosteric MEK1/2 inhibitor effective in human cancer cells (Wang et al., 2023). This evidence concerns the gene MAP2K1 and cancer.